JNJ vs LGN · P/E 17, rev $49.37B vs rev $2.55B
Johnson & Johnson (JNJ) versus Legence Corp. Class A Common stock (LGN) — a side-by-side from cached financials, not a winner call.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Legence Corp. Class A Common stock (LGN) is a engineering & construction company listed on NASDAQ.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Latest reported LGN revenue for 2025-12-31 was $2.55B. Net income was -$59.8M. Revenue was up 21.5% from 2024-12-31 to 2025-12-31. LGN currently screens at market cap $14.66B.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. LGN currently screens at market cap $14.66B.
Not investment advice. Open the JNJ and LGN stock pages for the full models.
Not investment advice.